S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
// Patrick Casara 1, * , James Davidson 2, * , Audrey Claperon 3, * , Gaëtane Le Toumelin-Braizat 3 , Meike Vogler 4 , Alain Bruno 5 , Maïa Chanrion 3 , Gaëlle Lysiak-Auvity 3 , Thierry Le Diguarher 1 , Jérôme-Benoît Starck 1 , Ijen Chen 2 , Neil Whitehead 2 , Christopher Graham 2 , Natalia Matassova 2 , Pawel Dokurno 2 , Christopher Pedder 2 , Youzhen Wang 6 , Shumei Qiu 6 , Anne-Marie Girard 3 , Emilie Schneider 3 , Fabienne Gravé 3 , Aurélie Studeny 3 , Ghislaine Guasconi 3 , Francesca Rocchetti 3 , Sophie Maïga 7 , Jean-Michel Henlin 1 , Frédéric Colland 3 , Laurence Kraus-Berthier 5 , Steven Le Gouill 7 , Martin J.S. Dyer 8 , Roderick Hubbard 2 , Mike Wood 2 , Martine Amiot 7 , Gerald M Cohen 9 , John A. Hickman 3 , Erick Morris 6 , James Murray 2 and Olivier Geneste 3 1 Institut de Recherches Servier Discovery Chemistry Unit, Croissy Sur Seine, France 2 Vernalis (R&D) Ltd., Cambridge, UK 3 Institut de Recherches Servier Oncology R&D Unit, Croissy Sur Seine, France 4 Institute for Experimental Cancer Research in Pediatrics, Goethe-University Frankfurt, Frankfurt, Germany 5 Institut de Recherches Internationales Servier, Oncology R&D Unit, Suresnes, France 6 Novartis Institute of Biomedical Research, Oncology Drug Discovery, Cambridge, MA, USA 7 CRCINA, INSERM, CNRS, Université de Nantes, CHU de Nantes, Nantes, France 8 Ernest and Helen Scott Haematological Research Institute, University of Leicester, Leicester, UK 9 Institute of Translational Medicine, University of Liverpool, Liverpool, UK * These authors contributed equally to this work Correspondence to: Olivier Geneste, email: olivier.geneste@servier.com Keywords: BCL-2; inhibitor; BH3-mimetics; apoptosis; hematological malignancies Received: September 12, 2017 Accepted: February 26, 2018 Published: April 13, 2018 ABSTRACT Escape from apoptosis is one of the major hallmarks of cancer cells. The B-cell Lymphoma 2 (BCL-2) gene family encodes pro-apoptotic and anti-apoptotic proteins that are key regulators of the apoptotic process. Overexpression of the pro-survival member BCL-2 is a well-established mechanism contributing to oncogenesis and chemoresistance in several cancers, including lymphoma and leukemia. Thus, BCL-2 has become an attractive target for therapeutic strategy in cancer, as demonstrated by the recent approval of ABT-199 (Venclexta™) in relapsed or refractory Chronic Lymphocytic Leukemia with 17p deletion. Here, we describe a novel orally bioavailable BCL-2 selective and potent inhibitor called S55746 (also known as BCL201). S55746 occupies the hydrophobic groove of BCL-2. Its selectivity profile demonstrates no significant binding to MCL-1, BFL-1 (BCL2A1/A1) and poor affinity for BCL-XL. Accordingly, S55746 has no cytotoxic activity on BCL-XL-dependent cells, such as platelets. In a panel of hematological cell lines, S55746 induces hallmarks of apoptosis including externalization of phosphatidylserine, caspase-3 activation and PARP cleavage. Ex vivo , S55746 induces apoptosis in the low nanomolar range in primary Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma patient samples. Finally, S55746 administered by oral route daily in mice demonstrated robust anti-tumor efficacy in two hematological xenograft models with no weight lost and no change in behavior. Taken together, these data demonstrate that S55746 is a novel, well-tolerated BH3-mimetic targeting selectively and potently the BCL-2 protein.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950 · cited 1×
“Toledo (Diffuse Large B-Cell Lymphoma) human cell lines were obtained internally through Bioresources and the NovartisCancer Cell Line Encyclopedia [43].”
MethodControl of apoptosis by the BCL-2 protein family: implications for physiology and therapy
Czabotar, P. E., Lessene, G., Strasser, A., & Adams, J. M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3722 · Cited by 3,219
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
Kotschy, A., Szlavik, Z., Murray, J., Davidson, J., Maragno, A. L., Le Toumelin-Braizat, G., Chanrion, M., Kelly, G. L., Gong, J.-N., Moujalled, D. M., et al. (2016) · Nature · doi:10.1038/nature19830 · Cited by 1,047
Self-citationProgrammed Anuclear Cell Death Delimits Platelet Life Span
Mason, K. D., Carpinelli, M. R., Fletcher, J. I., Collinge, J. E., Hilton, A. A., Ellis, S., Kelly, P. N., Ekert, P. G., Metcalf, D., Roberts, A. W., et al. (2007) · Cell · doi:10.1016/j.cell.2007.01.037 · Cited by 1,031
From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors
Ashkenazi, A., Fairbrother, W. J., Leverson, J. D., & Souers, A. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.253 · Cited by 903 · cited 1×
“Inhibiting these intracellular proteinprotein interactions is therefore an attractive strategy to target the aberrant survival of cancer cells caused by BCL-2 family dysregulation [10].”
BackgroundWilson, W. H., O'Connor, O. A., Czuczman, M. S., LaCasce, A. S., Gerecitano, J. F., Leonard, J. P., Tulpule, A., Dunleavy, K., Xiong, H., Chiu, Y.-L., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70261-8 · Cited by 876 · cited 7×
“Encouraging clinical activity against lymphoid malignancies thought to be BCL-2 dependent were observed in early trials with Navitoclax (ABT-263), the orally bioavailable analog of ABT-737 [12, 13, 14].”
BackgroundInfluentialThirty years of BCL-2: translating cell death discoveries into novel cancer therapies
Delbridge, A. R. D., Grabow, S., Strasser, A., & Vaux, D. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.17 · Cited by 752 · cited 1×
“Dysregulation of the BCL-2 family altering the balance between pro-survival and pro-death members provides a common mechanism by which cancer cells acquire a survival advantage [6].”
BackgroundLeverson, J. D., Phillips, D. C., Mitten, M. J., Boghaert, E. R., Diaz, D., Tahir, S. K., Belmont, L. D., Nimmer, P., Xiao, Y., Ma, X. M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4642 · Cited by 541 · cited 1×
“The recent discovery of selective BCL-XL [38, 39] and MCL-1 specific [40, 41] inhibitors is therefore of particular interest as these new specific BH3 mimetic compounds provide very promising strategies to overcome BCL-2 specific resistance mechanisms.”
BackgroundCircumventing cancer drug resistance in the era of personalized medicine
Garraway, L. A., & Jänne, P. A. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0012 · Cited by 503 · cited 1×
“com Target mutations causing resistance have been demonstrated with various high-affinity targeted therapies [34].”
Background
Cited by
Targeting apoptosis in cancer therapy
Carneiro, B. A., & El-Deiry, W. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0341-y · Cited by 2,542
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
BCL-2 family isoforms in apoptosis and cancer
Warren, C. F. A., Wong-Brown, M. W., & Bowden, N. A. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1407-6 · Cited by 700
Mechanisms of BCL-2 family proteins in mitochondrial apoptosis
Czabotar, P. E., & Garcia-Saez, A. J. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00629-4 · Cited by 680
Metadata
- Authors
- Casara, P., Davidson, J., Claperon, A., Le Toumelin-Braizat, G., Vogler, M., Bruno, A., Chanrion, M., Lysiak-Auvity, G., Le Diguarher, T., Starck, J.-B., Chen, I., Whitehead, N., Graham, C., Matassova, N., Dokurno, P., Pedder, C., Wang, Y., Qiu, S., Girard, A.-M., Schneider, E., Gravé, F., Studeny, A., Guasconi, G., Rocchetti, F., Maïga, S., Henlin, J.-M., Colland, F., Kraus-Berthier, L., Le Gouill, S., Dyer, M. J. S., Hubbard, R., Wood, M., Amiot, M., Cohen, G. M., Hickman, J. A., Morris, E., Murray, J., & Geneste, O.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2018-04-13
- Volume
- 9
- Issue
- 28
- Pages
- 20075-20088
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2793766280
- Cited by
- 118
- References
- 12
- FWCI
- 4.47
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth. https://app.cochat.ai/papers/10.18632/oncotarget.24744
- The paper
- Casara, P., Davidson, J., Claperon, A., Le Toumelin-Braizat, G., Vogler, M., Bruno, A., Chanrion, M., Lysiak-Auvity, G., Le Diguarher, T., Starck, J.-B., Chen, I., Whitehead, N., Graham, C., Matassova, N., Dokurno, P., Pedder, C., Wang, Y., Qiu, S., Girard, A.-M., . . . Geneste, O. (2018). S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth. Oncotarget. https://doi.org/10.18632/oncotarget.24744
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.